Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis

Abstract Background Mesenchymal stem cell (MSC) therapy shows great promise for diabetic kidney disease (DKD) patients. Research has been carried out on this topic in recent years. The main goals of this paper are to evaluate the therapeutic effects of MSCs on DKD through a meta-analysis and address...

Full description

Bibliographic Details
Main Authors: Wenshan Lin, Hong-Yan Li, Qian Yang, Guangyong Chen, Shujun Lin, Chunling Liao, Tianbiao Zhou
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Stem Cell Research & Therapy
Subjects:
Online Access:https://doi.org/10.1186/s13287-020-02108-5
id doaj-a3de4671058447b1b0b92e1184d7167f
record_format Article
spelling doaj-a3de4671058447b1b0b92e1184d7167f2021-01-10T12:13:20ZengBMCStem Cell Research & Therapy1757-65122021-01-0112112110.1186/s13287-020-02108-5Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysisWenshan Lin0Hong-Yan Li1Qian Yang2Guangyong Chen3Shujun Lin4Chunling Liao5Tianbiao Zhou6Department of Nephrology, the Second Affiliated Hospital of Shantou University Medical CollegeDepartment of Nephrology, Huadu District People’s Hospital of Guangzhou, Southern Medical UniversityDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical CollegeDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical CollegeDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical CollegeDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical CollegeDepartment of Nephrology, the Second Affiliated Hospital of Shantou University Medical CollegeAbstract Background Mesenchymal stem cell (MSC) therapy shows great promise for diabetic kidney disease (DKD) patients. Research has been carried out on this topic in recent years. The main goals of this paper are to evaluate the therapeutic effects of MSCs on DKD through a meta-analysis and address the mechanism through a systematic review of the literature. Method An electronic search of the Embase, Cochrane Library, ISI Web of Science, PubMed, and US National Library of Medicine (NLM) databases was performed for all articles about MSC therapy for DKD, without species limitations, up to January 2020. Data were pooled for analysis with Stata SE 12. Result The MSC-treated group showed a large and statistically significant hypoglycemic effect at 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, and 6 months. Total hypoglycemic effect was observed (SMD = − 1.954, 95%CI − 2.389 to − 1.519, p < 0.001; I 2 = 85.1%). The overall effects on serum creatinine (SCr) and blood urea nitrogen (BUN) were analyzed, suggesting that MSC decreased SCr and BUN and mitigated the impairment of renal function (SCr: SMD = − 4.838, 95%CI − 6.789 to − 2.887, p < 0.001; I 2 = 90.8%; BUN: SMD = − 4.912, 95%CI − 6.402 to − 3.422, p < 0.001; I 2 = 89.3%). Furthermore, MSC therapy decreased the excretion of urinary albumin. Fibrosis indicators were assessed, and the results showed that transforming growth factor-β, collagen I, fibronectin, and α-smooth muscle actin were significantly decreased in the MSC-treated group compared to the control group. Conclusion MSCs might improve glycemic control and reduce SCr, BUN, and urinary protein. MSCs can also alleviate renal fibrosis. MSC therapy might be a potential treatment for DKD.https://doi.org/10.1186/s13287-020-02108-5Mesenchymal stem cellDiabetic kidney diseaseAnimal studyClinical trialMeta-analysisSystematic review
collection DOAJ
language English
format Article
sources DOAJ
author Wenshan Lin
Hong-Yan Li
Qian Yang
Guangyong Chen
Shujun Lin
Chunling Liao
Tianbiao Zhou
spellingShingle Wenshan Lin
Hong-Yan Li
Qian Yang
Guangyong Chen
Shujun Lin
Chunling Liao
Tianbiao Zhou
Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis
Stem Cell Research & Therapy
Mesenchymal stem cell
Diabetic kidney disease
Animal study
Clinical trial
Meta-analysis
Systematic review
author_facet Wenshan Lin
Hong-Yan Li
Qian Yang
Guangyong Chen
Shujun Lin
Chunling Liao
Tianbiao Zhou
author_sort Wenshan Lin
title Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis
title_short Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis
title_full Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis
title_fullStr Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis
title_full_unstemmed Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis
title_sort administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis
publisher BMC
series Stem Cell Research & Therapy
issn 1757-6512
publishDate 2021-01-01
description Abstract Background Mesenchymal stem cell (MSC) therapy shows great promise for diabetic kidney disease (DKD) patients. Research has been carried out on this topic in recent years. The main goals of this paper are to evaluate the therapeutic effects of MSCs on DKD through a meta-analysis and address the mechanism through a systematic review of the literature. Method An electronic search of the Embase, Cochrane Library, ISI Web of Science, PubMed, and US National Library of Medicine (NLM) databases was performed for all articles about MSC therapy for DKD, without species limitations, up to January 2020. Data were pooled for analysis with Stata SE 12. Result The MSC-treated group showed a large and statistically significant hypoglycemic effect at 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, and 6 months. Total hypoglycemic effect was observed (SMD = − 1.954, 95%CI − 2.389 to − 1.519, p < 0.001; I 2 = 85.1%). The overall effects on serum creatinine (SCr) and blood urea nitrogen (BUN) were analyzed, suggesting that MSC decreased SCr and BUN and mitigated the impairment of renal function (SCr: SMD = − 4.838, 95%CI − 6.789 to − 2.887, p < 0.001; I 2 = 90.8%; BUN: SMD = − 4.912, 95%CI − 6.402 to − 3.422, p < 0.001; I 2 = 89.3%). Furthermore, MSC therapy decreased the excretion of urinary albumin. Fibrosis indicators were assessed, and the results showed that transforming growth factor-β, collagen I, fibronectin, and α-smooth muscle actin were significantly decreased in the MSC-treated group compared to the control group. Conclusion MSCs might improve glycemic control and reduce SCr, BUN, and urinary protein. MSCs can also alleviate renal fibrosis. MSC therapy might be a potential treatment for DKD.
topic Mesenchymal stem cell
Diabetic kidney disease
Animal study
Clinical trial
Meta-analysis
Systematic review
url https://doi.org/10.1186/s13287-020-02108-5
work_keys_str_mv AT wenshanlin administrationofmesenchymalstemcellsindiabetickidneydiseaseasystematicreviewandmetaanalysis
AT hongyanli administrationofmesenchymalstemcellsindiabetickidneydiseaseasystematicreviewandmetaanalysis
AT qianyang administrationofmesenchymalstemcellsindiabetickidneydiseaseasystematicreviewandmetaanalysis
AT guangyongchen administrationofmesenchymalstemcellsindiabetickidneydiseaseasystematicreviewandmetaanalysis
AT shujunlin administrationofmesenchymalstemcellsindiabetickidneydiseaseasystematicreviewandmetaanalysis
AT chunlingliao administrationofmesenchymalstemcellsindiabetickidneydiseaseasystematicreviewandmetaanalysis
AT tianbiaozhou administrationofmesenchymalstemcellsindiabetickidneydiseaseasystematicreviewandmetaanalysis
_version_ 1724343233915387904